Condition: Non Small Cell Lung Cancer NSCLC · Sponsor: Ono Pharmaceutical Co., Ltd.
The goal of this observational study is to learn about the effectiveness of Nivolumab in combination with chemotherapy as Neoadjuvant therapy for patients with non-small cell lung cancer (NSCLC). The main question it aims to answer is: Does patient with NSCLC in treatment of Nivolumab combined with chemotherapy demonstrate better pCR and PFS ? Is it safe for patient with NSCLC in treatment of Nivolumab combined with chemotherapy ? The data for those participants already receiving nivolumab in combination with chemotherapy as part of their regular medical care for NSCLC will be collected within the designated collection period.
This description comes directly from the study's public registry record.
Penny Medical Affairs Specialist, Clinical Pharmacology · 886-2-8786-9750 · penny.tsai@ono-pharma.com
Always discuss trial participation with your own doctor first.
| Chang Gung Memorial Hospital Kaohsiung Branch | Kaohsiung City, Taiwan | Recruiting |
| Kaohsiung Medical University Chung-Ho Memorial Hospital | Kaohsiung City, Taiwan | Recruiting |
| Kaohsiung Veterns General Hospital | Kaohsiung City, Taiwan | Recruiting |
| China Medical University Hospital | Taichung, Taiwan | Recruiting |
| Taichung Veterans General Hospital | Taichung, Taiwan | Recruiting |
| Mackay Memorial Hospital Taipei Branch | Taipei, Taiwan | Recruiting |
| National Taiwan University Hospital | Taipei, Taiwan | Recruiting |
| Taipei Veteran General Hospital | Taipei, Taiwan | Recruiting |
| Chang Gung Memorial Hospital Linkou Branch | Taoyuan, Taiwan | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07169708